Navigation Links
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.

"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) stud
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
4. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
5. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 2014   Royal Philips  (NYSE: PHG, AEX: PHIA) ... new ultrasound system designed to enable global hospitals and ... volumes and cost pressures. Making its debut at the  ... Barcelona this week, Affiniti provides innovative ... fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... 19 According to Millennium Research Group (MRG), the ... instituted under the Patient Protection and Affordable Care Act ... colorectal cancer screening for a large segment of the ... reimbursement, a growing number of colorectal cancer screening procedures ...
... Aug. 19 Boston Scientific Corporation (NYSE: ... studies involving the Company,s Women,s Health products will ... the International Continence Society (ICS) and International Urogynecological ... pelvic floor reconstruction systems and mid-urethral sling systems. ...
Cached Medicine Technology:New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014 2New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014 3Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 2Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 3Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 4Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 5
(Date:9/1/2014)... -- Watching action shows on TV may be bad for ... more snack food while watching action films and programs than ... "We find that if you,re watching an action movie while ... Aner Tal, of the Cornell Food and Brand Lab, said ... distracting the program is, the more you will eat." ...
(Date:9/1/2014)... 01, 2014 More than 200 Lipitor ... a federal litigation that continues to progress in the ... LLP reports. , A federal Case List published ... the widely-used cholesterol medication by plaintiffs who developed Type ... claims, Pfizer Inc. failed to adequately warn patients and ...
(Date:9/1/2014)... Spain Monday 1 September 2014: Daily fruit consumption ... to 40%, according to research presented at ESC Congress ... findings from the seven year follow-up study of nearly ... that the more fruit people ate, the more their ... including ischaemic heart disease (IHD) and stroke, is the ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... shared responsibility to a whole new level. Six ... $2 trillion in healthcare costs over the next decade. ... within our grasp.Blue Shield of California has long advocated ... are pleased that these groups are embracing the challenge ...
... 11, 2009 Iron chelating drugs have been heavily ... a form of blood cancer often treated with blood ... the body, are highly expensive and potentially toxic. A ... finds that their increased use has been propagated ...
... 11 Stephen J. Ubl, president and CEO of ... statement regarding today,s White House announcement of an industry ... are very pleased to join with President Obama and ... improving access to affordable, quality health care. As ...
... -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: GNPH) (the "Company"), ... People,s Republic,of China, today announced that its stock will ... the new ticker symbol "JGBO" as of May 12, ... symbol "GNPH" at the,end of May 11, 2009. , ...
... BlueCross BlueShield Give 40 in District Opportunity to Help Community Prevent HIV/AIDS ... ... and Education ( SHIRE ), Inc., is reaching out to 40 young ... help prevent the spread of HIV and AIDS and childhood obesity. ...
... Medical TechnologyWASHINGTON, May 11 Patients from across the ... about how medical technology has helped improve or save ... House of Representatives Energy & Commerce Committee hearing on ... repeal the Food and Drug Administration,s (FDA) preemption authority. ...
Cached Medicine News:Health News:AdvaMed Pleased to Work with the White House to Advance Health Reform 2Health News:Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 3Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 4Health News:Patients Call for Continued FDA Preemption Authority 2Health News:Patients Call for Continued FDA Preemption Authority 3Health News:Patients Call for Continued FDA Preemption Authority 4
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
... LeibingerTitanium Microplus System is a ... skeletal fixation armamentarium. It may ... vault, nasal, zygomatic and orbital ... especially where increased strength over ...
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Medicine Products: